Financial reports
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
10-Q
2023 Q2
Quarterly report
16 Aug 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
23 Feb 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
Current reports
8-K
Bankruptcy or Receivership
28 Feb 24
8-K
Other Events
12 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Nov 23
8-K
Changes in Registrant's Certifying Accountant
25 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
13 Oct 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
29 Sep 23
8-K/A
Financial Statements and Exhibits
7 Sep 23
8-K
Entry into a Material Definitive Agreement
5 Sep 23
8-K
Entry into a Material Definitive Agreement
25 Aug 23
Registration and prospectus
25-NSE
Exchange delisting
15 Feb 24
424B3
Prospectus supplement
22 Nov 23
S-1/A
IPO registration (amended)
21 Sep 23
S-3/A
Shelf registration (amended)
21 Sep 23
S-1
IPO registration
5 Sep 23
8-A12G
Registration of securities
24 Aug 23
424B5
Prospectus supplement for primary offering
18 Aug 23
424B3
Prospectus supplement
17 Aug 23
S-3
Shelf registration
28 Jun 23
424B3
Prospectus supplement
28 Apr 23
Proxies
DEFA14A
Additional proxy soliciting materials
10 Oct 23
DEF 14A
Definitive proxy
7 Sep 23
DEFA14A
Additional proxy soliciting materials
7 Sep 23
DEFA14A
Additional proxy soliciting materials
5 Sep 23
PRER14A
Preliminary revised proxy
25 Aug 23
DEFA14A
Additional proxy soliciting materials
21 Aug 23
DEFA14A
Additional proxy soliciting materials
9 Aug 23
DEFA14A
Additional proxy soliciting materials
31 Jul 23
PRE 14A
Preliminary proxy
31 Jul 23
DEFA14A
Additional proxy soliciting materials
25 Jul 23
Other
EFFECT
Notice of effectiveness
26 Sep 23
EFFECT
Notice of effectiveness
26 Sep 23
CORRESP
Correspondence with SEC
21 Sep 23
CORRESP
Correspondence with SEC
21 Sep 23
UPLOAD
Letter from SEC
13 Sep 23
UPLOAD
Letter from SEC
26 Jul 23
EFFECT
Notice of effectiveness
27 Apr 23
CORRESP
Correspondence with SEC
26 Apr 23
CORRESP
Correspondence with SEC
26 Apr 23
CORRESP
Correspondence with SEC
26 Apr 23
Ownership
SC 13G/A
BLACK HORSE CAPITAL LP
14 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
3
Natalie McAndrew
11 Oct 23
3
Yong Chan Kim
13 Jul 23
SC 13G/A
BLACK HORSE CAPITAL LP
10 Jul 23
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
4
GERALDINE HENWOOD
19 Dec 22
SC 13G
INTRACOASTAL CAPITAL, LLC
6 Sep 22
4
William Ashton
17 Jun 22